ATYR insider transactions
aTyr Pharma Inc. (ATYR) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
Recent Form 3, 4, and 5 filings for ATYR
- President and CEO Shukla Sanjay converted options into 10,375 shares and sold $3,655 worth of shares (3,745 units at $0.98), increasing direct ownership by 5% to 153,553 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- Chief Financial Officer Broadfoot Jill Marie converted options into 3,750 shares and sold $1,521 worth of shares (1,558 units at $0.98), increasing direct ownership by 6% to 37,296 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- General Counsel Denyes Nancy converted options into 2,687 shares and sold $1,091 worth of shares (1,118 units at $0.98), increasing direct ownership by 5% to 33,124 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by President and CEO Shukla Sanjay4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Broadfoot Jill Marie4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by General Counsel Denyes Nancy4 - aTYR PHARMA INC (0001339970) (Issuer)
- Director Schimmel Paul bought $911,801 worth of shares (1,000,000 units at $0.91) (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Director Zaknoen Sara4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Director Schimmel Paul4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Director Lucas Svetlana4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Director Gross Jane A4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Director Benevich Eric4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Director Coughlin Timothy4 - aTYR PHARMA INC (0001339970) (Issuer)
- Director Gross Jane A bought $15,000 worth of shares (3,750 units at $4.00), increasing direct ownership by 62% to 9,750 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- President and CEO Shukla Sanjay converted options into 10,375 shares, increasing direct ownership by 8% to 146,923 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- Chief Financial Officer Broadfoot Jill Marie converted options into 3,750 shares and sold $4,740 worth of shares (1,254 units at $3.78), increasing direct ownership by 9% to 31,763 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- General Counsel Denyes Nancy sold $3,398 worth of shares (899 units at $3.78) and converted options into 2,687 shares, increasing direct ownership by 7% to 26,555 units (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by President and CEO Shukla Sanjay4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Broadfoot Jill Marie4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by General Counsel Denyes Nancy4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 4 filed by Director Benevich Eric4 - aTYR PHARMA INC (0001339970) (Issuer)
- SEC Form 3 filed by new insider Benevich Eric3 - aTYR PHARMA INC (0001339970) (Issuer)
- Director Schimmel Paul bought $184,613 worth of shares (100,000 units at $1.85) (SEC Form 4)4 - aTYR PHARMA INC (0001339970) (Issuer)